Lifeward broadens coverage for ReWalk 7 Personal Robotic Exoskeleton

Lifeward (LFWD) announced that it received prior authorization from Humana Medicare Advantage Plan for a ReWalk 7 Personal Exoskeleton. This marks the second national Medicare Advantage Plan, following UnitedHealthcare (UNH) a few weeks ago, to make the important decision to support members living with spinal cord injury by facilitating access to this life-changing technology. “Nationally nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for ReWalk 7,” said Mark Grant, CEO of Lifeward. “This prior authorization approval from a Humana Medicare Advantage Plan represents another significant milestone in payer adoption of the ReWalk Exoskeleton. As coverage broadens and prior authorizations accelerate, we are seeing stronger predictability in reimbursement, healthier cash flow dynamics, and a clearer foundation for scalable, sustainable growth in the U.S. market.”